demoworker @demoworker
27 July, 04:19
Beneficios
#nutricion
demoworker @demoworker
27 July, 04:18
Beneficios del apio
#salud #nutricion
demoworker @demoworker
27 July, 04:00 (E)
💥 ATENCIÓN SERVICIOS TECNICOS 💥
Puedo ayudarte con tu crecimiento en las redes sociales 📺 y conseguirte más clientes 💥.

Https://Info.miopcionsalud...
demoworker @demoworker
27 July, 03:59
💥 ATENCIÓN SERVICIOS TECNICOS 💥
Puedo ayudarte con tu crecimiento en las redes sociales 📺 y conseguirte más clientes 💥.

Rellena el formulario para tu consulta gratuita:
Mashwishi @Mashwishi
09 June, 05:16 (E)
ColibriSM - PWA Module for iOS and Android with Offline Fallback for only $15 thru Ko-fi using paypal or You can message me here for the crypto transaction.

Product: https://ko-fi.com/s/b8616d...
Version Support: 1.3.2-1.3.3

Supported Crypto Payment:
USDT, BTC, ETH, BNB

Tags: #colibrism #colibrismpwa #pwa #iOS #android #feature #module
Anderson Madeira @afmadeira
08 June, 04:07
Anime Music @animemusic
18 April, 10:11
Anime Music @animemusic
18 April, 07:32
Steffan Joe @go_62036dc494e07
08 March, 07:36
CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis

Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.

Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.

To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis....

Key Market Insights

Over 75 CD-47 drug candidates are under various phases of development
52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively.

~50 companies claim to be engaged in the development of CD-47 therapeutics, globally
Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US.

Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%).

Partnership activity within this domain has increased at a CAGR of 25.7%, between 2016 and 2020
Clinical trial agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development and commercialization agreements (25%), licensing agreements (25%), and services agreements (7.1%).

USD 3.3+ billion has been invested by both private and public investors
It is important to mention that, between 2016 and 2021, majority of the funding amount was raised through secondary offerings (46.5%), venture capital rounds (45%), IPO (15.6%) and debt financing (7.4%).

North America is anticipated to capture over 85% of the market share, by 2035
The market will be primarily driven by sales of CD-47 based therapeutics designed as biologics (over 60%), followed by those developed as small molecules (over 39%). Further, CD-47 based therapies targeting non-small cell lung cancer will capture the dominant share (23%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis....

Key Questions Answered

 Who are the leading players engaged in the development of CD47 targeting therapeutics?
 Which are the key drugs being developed across early and late stages of development?
 Which companies are actively involved in conducting clinical trials for their therapeutics?
 What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?
 What kind of partnership models are commonly adopted by industry stakeholders?
 Who are the key investors in this domain?
 Who are the key opinion leaders / experts in this field?
 What are the evolving social media trends related to CD47 targeting therapeutics?
 What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?
 How is the current and future opportunity likely to be distributed across key market segments?

The financial opportunity within the CD-47 targeting therapeutics market has been analyzed across the following segments:
 Type of Molecule
 Biologics
 Small molecules

 Target Indications
 Acute Myeloid Leukemia
 Colorectal Neoplasms
 Diffuse-Large Cell Lymphoma
 Myelodysplastic Syndromes
 Non-Hodgkin Lymphoma
 Non-Small Cell Lung Cancer
 Oral Muscositis
 Ovarian Epithelial Cancer
 Small Cell Lung Cancer

 Key Players

 Key Geographical Regions
 US
 France
 Germany
 Italy
 Spain
 UK
 Australia
 China
 India
 Israel

The research includes detailed profiles of 10+ developers by (listed below); the profiles also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.

 Abpro
 ALX Oncology
 Apmonia Therapeutics
 Arch Oncology
 Aurigene
 Bristol Myers Squibb
 EpicentRx
 Forty Seven
 ImmuneOncia Therapeutics
 ImmuneOnco Biopharmaceuticals
 Innovent Biologics
 KAHR Medical
 Light Chain Bioscience
 Morphiex
 Trillium Therapeutics

For additional details, please visit
https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Squamous NSCLC Market, 2021-2031
3. Peptide Therapeutics Market, 2021-2031

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
applecarplay applecarplay @applecarplay
06 March, 02:05
Après la mise à niveau du téléphone mobile vers iOS 15.2, certains cyclistes ont rencontré le problème que la carte AutoNavi Baidu ne sffichait pas lors de lutilisation de apple carplay, lécran de navigation sur lécran de verrouillage était bloqué et le logiciel de musique ne lisait pas de musique.

La solution la plus efficace à lheure actuelle est de fermer le logiciel utilisé sur le téléphone mobile et de le rouvrir à nouveau. Par exemple, si vous utilisez la carte AutoNavi, vous pouvez désactiver la carte AutoNavi sur votre téléphone mobile, puis rouvrir la carte AutoNavi pour afficher la carte normalement dans CarPlay. Le logiciel de musique est également une opération similaire.
https://applecarplay.co/
Steffan Joe @go_62036dc494e07
01 March, 07:29
Site management organizations (SMO) market is projected to grow at an annualized rate of ~10% during the period 2021-2035.
In addition to being a time and cost intensive process, clinical trials are fraught with several challenges; considering the expertise available with site management organizations (SMOs) to conduct such studies in an efficient manner, trial sponsors are actively outsourcing their requirements

Roots Analysis is pleased to announce the publication of its recent study, titled, “Site Management Organizations (SMO) Market, 2021–2035.”

The study features an in-depth analysis, highlighting the capabilities of clinical trial site management service providers engaged in this domain. Amongst other elements, the report features:
 A detailed assessment of the current market landscape of companies offering clinical trial site management services.
 A competitiveness analysis of various service providers segregated into three peer groups based on location of their headquarters (North America, Europe, and Asia-Pacific and RoW). The companies were further distributed across the geographies, based on their employee count, into three categories, namely small (500 employees).
 Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) that offer various clinical trial site management services, across North America, Europe and Asia-Pacific.
 An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021 (till August).
 A detailed analysis of various investments received by players engaged in this domain during the period 2015-2021 (till August).
 An in-depth analysis of completed, ongoing and planned clinical studies during the period 2016-2021 (till August).
 An informed estimate of the annual demand for clinical study participants, based on various relevant parameters, for the period 2021-2035.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
 Therapeutic Areas
 Oncological Disorders
 CNS Disorders
 Infectious Diseases
 Respiratory Disorders
 Cardiovascular Diseases
 Endocrine Disorders
 Gastrointestinal Disorders
 Musculoskeletal Diseases
 Immunological Disorders
 Others

 Trial Phases
 Phase I
 Phase II
 Phase III
 Phase IV

 Clinical Trial Components
 Site Management
 Onsite Monitoring
 Project Management
 Data Management
 Regulatory Affairs
 Logistics
 Quality Control
 Others

 Types of Interventions
 Therapeutics
 Devices
 Surgical Procedure

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 MENA
 Rest of the World

 Transcripts of interviews held with the following senior level representatives of stakeholder companies
 Vinod Gyanchandani (Country Head - Clinical Operations, GDD Experts)
 Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico)
 Eugene Winifred (Project Manager, Syncretic Clinical Research Services)

Key companies covered in the report
 FOMAT Medical Research
 Parexel
 Pharm-Olam
 Veristat
 WCCT Global
 Worldwide Clinical Trials
 CROMSOURCE
 Fidelis Research
 Scandinavian CRO
 TFS HealthScience
 Trialbee
 CMIC
 George Clinical
 Tigermed
 Veeda Clinical Research

For more information, please click on the following link:
https://www.rootsanalysis....

You may also be interested in the following titles:
1. Patient Recruitment and Retention Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
3. Clinical Trial Planning and Design Services Market: Industry Trends and Global Forecasts, 2021-2030
4. Biospecimen Contract Research Services Market: Industry Trends and Global Forecast, 2021-2030
5. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Mason Joe @go_6207581baf031
25 February, 07:49
The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030.

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”

The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
 A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
 Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
 A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
 A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
 A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
 A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
 An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
 A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
 An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
 An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
 A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
 A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
 A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
 A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Commonly Outsourced Business Operations
 Active Pharmaceutical Ingredients (API)
 Finished Dosage Formulations (FDF)
 Types of Expression System
 Mammalian
 Microbial
 Others
 Company Size
 Small
 Mid-Sized
 Large and Very Large
 Scale of Operation
 Preclinical
 Clinical
 Commercial
 Key Geographical Region
 North America
 Europe
 Asia-Pacific
 Rest of the World

The report also features detailed transcripts of discussions held with the following experts:
 Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
 Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
 Christian Bailly, Director of CDMO, Pierre Fabre
 Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
 David C Cunningham, Director Corporate Development, Goodwin Biotechnology
 Dietmar Katinger, Chief Executive Officer, Polymun Scientific
 Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
 Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
 Kevin Daley, Director Pharmaceuticals, Novasep
 Mark Wright, Site Head, Grangemouth, Piramal Healthcare
 Nicolas Grandchamp, R&D Leader, GEG Tech
 Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
 Sebastian Schuck, Head of Business Development, Wacker Biotech
 Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
 Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
 Tim Oldham, Chief Executive Officer, Cell Therapies

Key companies covered in the report
 3P Biopharmaceuticals
 Abzena
 Albany Molecular Research
 BioVectra
 BioXcellence (Boehringer Ingelheim)
 Celonic
 Charles River Laboratories
 ChemPartner
 Cobra Biologics
 CordenPharma
 Cytovance Biologics
 GE Healthcare
 Goodwin Biotechnology
 Grand River Aseptic Manufacturing
 IDT Biologika
 KBI BioPharma
 Kemwell Biopharma
 LFB Biomanufacturing
 Meridian Life Science
 Patheon
 Pfizer CentreOne
 PXTherapeutics
 Samsung BioLogics
 Sanofi, CEPiA
 Thermo Fisher Scientific
 Vetter Pharma International

For more information please click on the following link:
Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030

Other Recent Offerings
1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
2. Antibody Contract Manufacturing Market, 2020-2030
3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

About Roots Analysis
Roots Analysis is one of the fastest growi
Michael Doe @go_620609f9cd878
24 February, 07:48
The globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products.

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.

To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this - https://www.rootsanalysis....

The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:
 Types of Primary Packaging Containers
 Ampoules
 Cartridges
 Syringes
 Vials

 Types of Biologics
 Peptides / proteins
 Antibodies
 Vaccines
 Cell therapies
 Gene therapies
 Viral products
 Oligonucleotides
 Others

 Company Size
 Small-sized
 Mid-sized
 Large / very large

 Scale of Operation
 Preclinical
 Clinical
 Commercial

 Key Therapeutic Areas
 Cancer
 Infectious diseases
 Autoimmune diseases
 Cardiovascular diseases
 Other indications

 Key Geographical Regions
 North America (US, Canada)
 Europe (UK, France, Germany, Italy, Spain and rest of the Europe)
 Asia-Pacific (Japan, China, South Korea, India and Australia)

The Biologics Fill / Finish Services Market, 2019-2030.”report features the following companies, which we identified to be key players in this domain:
 Advanced BioScience Laboratories (ABL)
 Albany Molecular Research (AMRI)
 Biocon
 BioPharma Solutions
 BioReliance
 Boehringer Ingelheim BioXcellence
 ChemPartner
 Emergent BioSolutions
 IDT Biologika
 Lonza
 LuinaBio
 Mycenax Biotech
 Patheon
 Recipharm
 Vetter Pharma
 WuXi Biologics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Competitive Landscape

5. Company Competitiveness Analysis

6. Biologics Fill / Finish Service Providers in North America: Company Profiles

7. Biologics Fill / Finish Service Providers in Europe: Company Profiles

8. Biologics Fill / Finish Service Providers in Asia-Pacific: Company Profiles

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Demand Analysis

13. Biologics Manufacturing and Fill / Finish: Key Performance Indicator Analysis

14. Market Sizing and Opportunity Analysis

15. Future Growth Opportunities

16. Case Study: Robotic Systems in Fill / Finish Operations

17. Case Study: Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis....

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...
Michael Doe @go_620609f9cd878
24 February, 07:40
Clinical Trial Planning and Design Services Market by Phase of Trial, Industry Trends and Global Forecasts, 2021-2030.

Roots Analysis has announced the addition of Clinical Trial Planning and Design Services Market report to its list of offerings.

During our research, we were able to identify 46 industry players that are engaged in offering clinical trial planning and design services. The clinical trial planning and design services domain is presently dominated by the presence of large firms (70%), followed by mid-sized companies (18%). most of the players engaged in this domain offer study design / protocol development (96%), followed by those providing sample size and power analysis services (83%). Notable examples of players offering more than four services include (in alphabetical order), Cancer Research And Biostatistics (1997), Peter MacCallum Cancer Centre (1949), Singapore Clinical Research Institute (2008) and University of Arizona College of Medicine (2006).

To request a sample copy / brochure of this report, please visit this – https://www.rootsanalysis....

Over the years, clinical research has undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Clinical research involves a thorough literature review that helps to collate information on studies that involve interactions with patients and diagnostic clinical trial data, in order to understand the root cause of a disease and its treatment. It is worth highlighting that clinical research involves two major steps, namely study design and study reporting. Further, study design involves three key steps, theoretical design, data collection design and statistical analysis design. Specifically, experimental or non-experimental data collection, sampling or census data collection, and temporal characteristics of the variables to be examined are all aspects of data collection design. On the other hand, study reporting includes guiding principles to carry out concise, explicit and elaborative research.

 Planning Period: This parameter takes into consideration the time period that is required to draw up the protocol, as well as to define the objectives of the trial. It is worth highlighting that the period for planning a clinical trial can take up to a year.
 Duration of a Trial: It takes into consideration the amount of time required to recruit participants, as well as to monitor their reaction and survival rate.
 Comparability of Patients: It takes into consideration the comparability of enrolled patient population with respect to prognostic factors. It is worth mentioning that prognostic factors define the enrolled patient population, help to formulate the objectives of the trial, and provide better treatment strategies. These factors provide valid estimates of the differences in the given treatment and help to evaluate results across different studies.
 Treatment Allocation Ratio: This step helps to reduce bias, balanced comparison between two treatment groups and quantification of errors. It is worth highlighting that patients can be allocated to two different trials at the same time; however, in such cases, patients are usually allocated randomly in a 60:40 or 2:1 ratio.
 Use of Historical Control Group: Historical control group can be used to estimate model parameters during the research design phase, to modify a study, or to augment or replace a control arm. Most of the clinical trials include a control group of patients who have the same characteristics as the specially treated group; however, these patients are not administered with the drug / therapy treatment.
 Treatment Management: The treatment provided to enrolled patients should be administered equally, regardless of their treatment plan. Further, in each therapy group, patients should have the same criteria of response and toxicity.
 Ethical Considerations: Ethical concerns can arise at any point throughout the trial. It is worth mentioning that conditions under which a patient may be withdrawn from the study should be carefully examined, prior to the trial. Further, an international review board must approve all human-related research projects.

To request a free insight to this report - https://www.rootsanalysis....

Key Questions Answered
 Who are the key players engaged in offering clinical trial planning and design services, across the world?
 What are the regulatory guidelines established in different geographies and their requirements related to clinical trial planning and design?
 What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
 What are the key value drivers of the merger and acquisition activity observed within this domain?
 How is the current and future market opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to clinical trial planning and design services?

For additional details, please visit - https://www.rootsanalysis.... Or salesrootsanalysis.com

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Steffan Joe @go_62036dc494e07
22 February, 07:40
The modular facilities market is estimated to be worth USD 6.4 billion in 2030, predicts Roots Analysis.

Off-site, modular construction minimizes disruption to building timelines and logistical delays, ensuring systematic delivery of new facilities, this is particularly beneficial within the healthcare industry, where speed, sanitation and sterility are crucial

Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market”

To Request Sample Page - https://www.rootsanalysis....

The report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

 An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers.
 A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications.
 An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021.
 An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility.
 An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players.
 Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries.
 An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.
 A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

For additional details, please visit - https://www.rootsanalysis....

 Type of Modular Construct
 Hybrid Skid
 Plug-and-Play
 Skid-Mounted
 Truckable
 Others
 Type of Construction Component
 Base Building
 Electrical System
 Mechanical System
 Process Equipment
 Process Piping
 Process Utilities
 Other Components
 Purpose of Facility
 Aseptic Filling
 Manufacturing
 Research and Development
 Others
 Facility Area
 Very Small
 Small
 Mid-Sized
 Large
 Very Large
 Scale of Operation
 Clinical
 Commercial
 Type of Industry
 Pharmaceutical
 Biotechnology
 Type of Product
 Biosimilars
 Cell and Gene Therapies
 Monoclonal Antibodies
 Vaccines
 Other Products
 Type of Facility
 New Facility
 Facility Expansions
 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

Download Free Insights now - https://www.rootsanalysis....

Transcripts of interviews held with the following senior level representatives of stakeholder companies
Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)
 François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)
 Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)
 Pär Almhem (President, Modwave)
 Sulogna Roy (Ex Sales Manager, Zeton)
 Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

Key companies covered in the report
 Cytiva
 G-CON Manufacturing
 Pharmadule Morimatsu
 NNE
 IPM Technologies
 KeyPlants
 Germfree Laboratories
 ModuleCO Pharma

For more information, please click on the following link
https://www.rootsanalysis....

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. Biopharmaceutical CROs Market, 2021-2030
3. Continuous Manufacturing Equipment Providers Market, 2021-2030
4. DNA-Encoded Libraries: Platforms and Services Market
5. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudharyrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.